Objective: To examine use of complementary and alternative medicine (CAM) among individuals with radiographic-confirmed osteoarthritis (OA) of the knee. Methods: We included 2679 participants of the Osteoarthritis Initiative with radiographic tibiofemoral knee OA in at least one knee at baseline. Trained interviewers asked a series of specific questions relating to current OA treatments including CAM therapies (seven categories e alternative medical systems, mind-body interventions, manipulation and body-based methods, energy therapies, and three types of biologically based therapies) and conventional medications. Participants were classified as: (1) conventional medication users only, (2) CAM users only; (3) users of both; and (4) users of neither. Polytomous logistic regression identified correlates of treatment approaches including sociodemographics and clinical/functional correlates.
Introduction
By the year 2020, 59.4 million persons in the United States will be affected by arthritis 1 . Osteoarthritis of the knee (OAK) is the leading cause of disability in the United States 2 , and population-based projections of the probable need for total knee arthroplasty indicate steady increases in all age groups 3 . Patients suffering from OAK seek effective treatments (e.g., physical or occupational therapy, weight loss, pharmacologic approaches) for pain relief, as well as minimizing functional limitations of symptoms and to attempt to slow disease progression 4 . In additional to conventional medications, complementary and alternative medicine (CAM) (including herbal remedies, acupuncture, supplements) 5 increasingly are used. Indeed, arthritis is among the top six conditions for which CAM is used 6 . Previous reports have demonstrated that CAM use differs by age group 7 , gender 8 , race/ethnicity 9, 10 , educational attainment 11 , annual household income, employment status 8 , and health insurance status. However, the extent to which the existing literature on CAM use (based on self-report) extends to a population with radiographic confirmation of OAK is unknown. Also, standardized measures of performance, function, quality of life and pain are frequently absent from studies of CAM among persons with OAK. Lastly, most studies of CAM use describe correlates of CAM use only, and have not differentiated the use a combination of CAM and conventional medical approaches. Thus, we examined the use of CAM and conventional medication approaches in a large number of participants of the Osteoarthritis Initiative (OAI).
Subjects and methods
The Institutional Review Boards of Virginia Commonwealth University and the Memorial Hospital of Rhode Island approved the study protocol.
Data source
We used publicly available data from the OAI (http://www.oai. ucsf.edu/) (#AllClinical00, V0.2.2). The OAI began enrolling people aged 45 through 79 years in 2004 and followed them annually for the development or progression of OAK. The clinical sites involved were Baltimore, MD; Columbus, OH; Pittsburgh, PA; and Pawtucket, RI. Participants were ineligible if any of the following were present: (1) rheumatoid arthritis or inflammatory arthritis; (2) severe joint space narrowing in both knees or unilateral total knee arthroplasty and severe joint space narrowing in the contralateral knee; (3) inability to undergo 3.0 T magnetic resonance imaging (MRI) examination of the knee; (4) a positive pregnancy test; (5) inability to provide a blood sample; (6) use of ambulatory aids aside from the use of a single straight cane for 50% of ambulation time or more; (7) co-morbid conditions that might interfere with ability to participate in a study with a 4-year follow-up time; or (8) unlikelihood to reside in the clinic area for at least 3 years 12 . The overall study included 4796 participants.
Study sample
For the current study, we included individuals with radiographic tibiofemoral OAK in at least one knee at baseline (N ¼ 2679). Readers from each clinical site were trained to assess baseline fixed flexion knee X-rays for osteophytes and joint space narrowing. Training consisted of a didactic and interactive components using a web-based system that included scoring a training set of knee X-rays. Radiographic tibiofemoral OAK was defined as the presence of an Osteoarthritis Research Society International (OARSI) atlas osteophyte grade 1e3 (equivalent to Kellgren and Lawrence grade 2) on a fixed flexion radiograph based on the readings results provided by the individual clinical sites 13 .
Exposure categories
We decided to create a four level variable to simultaneously categorize participants according to their CAM and conventional medication use. Previously, reports have focused on correlates of CAM use, without regarding use of conventional medications. Yet, we speculated that use of both strategies were common and that the factors associated with monotherapy (CAM or conventional), may be different to those associated with use of combined therapies.
Participants were asked "During the past 30 days, have you used any of the following medications for joint pain or OA on most days? By most days, we mean more than half the days of the month." Participants were asked separate questions for: acetaminophen, over-the-counter non-steroidal anti-inflammatory agents (NSAIDs), prescription NSAIDs, prescription cyclooxygenase-2 (COX-2) inhibitors, doxycycline and prescription "strong pain" medications such as opioids. Interviewers asked "During the past 6 months, did you use the following health supplements for joint pain or arthritis?" with separate questions for chondroitin sulfate and glucosamine. A series of questions specifically asked about the use of CAM approaches for arthritis or joint pain during the past year, as well as how frequently practitioners were seen. Responses from these questions were used to classify participants as: conventional medication users only, CAM users only, both CAM and conventional users, and users of neither.
Medications often used in the management of OAK included use of acetaminophen, over-the-counter NSAIDs (e.g., aspirin, ibuprofen, naproxen), NSAIDs requiring a prescription (e.g., ibuprofen at higher doses, diclofenac, naproxen), COX-2 selective inhibitors (e.g., valdecoxib, rofecoxib, celecoxib), hyaluronic acid, steroids/injected corticosteroids, and calcitonin. To differentiate from CAM, we labeled these treatments as conventional medications. We considered CAM 5 as any indication of use of: (1) alternative medical systems (acupuncture, acupressure, homeopathy and others); (2) mind-body interventions (yoga/Tai Chi/Chi Gong/pilates, spiritual activities, relaxation therapy, meditation, deep breathing or visualization); (3) manipulation and body-based methods (Chiropractic and massage); (4) energy therapies (copper bracelets or magnets); (5) topical biologically based therapies including rubs, lotions, liniments, creams or oils (tiger balm, horse liniment), capsaicin; (6) biologically based diet; or (7) biologically based supplements (e.g., herbals, glucosamine, chondroitin, vitamins/minerals, methylsulfonylmethane (MSM), S-adenosylmethionine (SAME)). Because glucosamine and chondroitin are not considered as CAM in some countries, we also separated the use of glucosamine and chondroitin from other CAM treatments.
Potential correlates
Based on a non-systematic literature review, we considered several conceptual domains as potential correlates of treatment approach for OA: sociodemographic indicators, body mass index (BMI), overall measures of mental and physical wellbeing, and clinical indices of OAK. We hypothesized that CAM use would be different by age group 7 , gender 8 , race/ethnicity 9, 10 , educational attainment 11 , annual household income, employment status 8 , and health insurance status. Gender, age, and race/ethnicity were based on selfreport. Participants were considered employed if they reported currently working or planning to return to work within 6 months. Health insurance coverage status was identified as "currently having private health insurance, prepaid plans, Preferred Provider Organizations or any government-sponsored plans". Participants were also classified as having insurance that covered prescription medications.
In the general population, obesity is inversely related to use of CAM 14 . , we only used the pain scale. Each of the five items of the pain scale contains five Likert responses, ranging from '0 ¼ none' to '4 ¼ extreme', which were summed to produce the pain subscale scores (maximum score 20 indicating the worst pain). We also used the Knee Outcomes in Osteoarthritis Survey (KOOS) as an indicator of knee related quality of life. The KOOS assesses knee symptoms and function during more demanding activities (e.g., during sport and recreation) 20 . The KOOS quality of life scale was estimated by summing the responses to four items with five Likert responses, ranging from 0 to 4 and computing a normalized score ranging from 0 to 100 (100 indicating no symptoms and 0 indicating extreme symptoms). For the WOMAC and KOOS measures, we evaluated the right and left knees separately and used the knee with worse measures. For measures of performance and function we used a 20-m walk to measure walking ability and endurance 21 . The average duration (seconds) of completing the 20-m walk was calculated based on two trials. The chair stand test was used as a direct assessment of integrated physical performance involving leg strength and knee function 22 . The chair stand time was defined as the time duration (seconds) of standing up and sitting down five times as quickly as possible. Disease severity was measured in two ways. First, we classified participants by the X-ray joint space narrowing as determined by the OARSI atlas osteophyte grade 1e3 (equivalent to Kellgren and Lawrence grade 2) on a fixed flexion radiograph 13 . The worst measure of two knees was used. Second, to capture multiple-joint OA symptoms we considered: low back pain in previous 30 days, OA in hand, hip symptoms, hip replacement and knee injury history (including knee injury and knee surgery) as reported at baseline.
Statistical analyses
We compared the sociodemographic and clinical characteristics of users in each group (conventional medication use only, CAM use only, use of both CAM and conventional medications) to the referent group e non-users of CAM/conventional medications by conducting chi-square tests for categorical data and t-tests for continuous variables. Rather than overall chi-square tests, each group was compared to the referent group. Next, we used polytomous logistic regression modeling to identify correlates of treatment approaches by comparing the odds of using conventional medications only, using CAM approaches only, using both CAM and conventional approaches with non-users. In our polytomous logistic regression model, the outcome variable represented four categories. The models for each (three models for four categories) are simultaneously fit by using maximum likelihood to estimate adjusted odds ratios (aOR) for each group compared with a common reference group 23 . Before modeling we evaluated (and ruled out) the potential for multicollinearity amongst the potential correlate variables under study by checking correlations between the covariates. When two variables were correlated (e.g., education and income), we elected to include only one of the variables (e.g., education) in our final model. During the modeling process, the standard errors for the variables were also evaluated for indications of multicollinearity. If inflated standard errors were apparent, we dropped one of the collinear variables from the model. We used an iterative, but not computer driven approach to develop the final model of correlates. To provide more clinically meaningful results for the SF-12 Physical Scale, WOMAC-Pain, and KOOS-Quality of Life (QOL), we provide odds ratios for a one standard deviation change in each variable. To further differentiate correlates amongst the different CAM approaches, we created a separate polytomous logistic regression model with the following outcome variable: use of glucosamine/chondroitin only, use of other CAM approaches only, using both CAM and conventional approaches and non-users. The same modeling strategies described above were applied to this model.
Results
The majority of the sample was white, well educated, and covered by health insurance. Use of CAM was common (47%, 95% confidence interval (CI): 45e49%). Sixteen percent (95% CI: 15e18%) used conventional medications only, 23% (95% CI: 21e25%) used CAM only, and 24% (95% CI: 22e26%) used both CAM and conventional medications. Table I shows the specific types of CAM used. Forty-seven percent reported use of at least one CAM method. Of these, 32% (95% CI: 29e35%) reported use of at least two CAM approaches. The use of biologically based supplements was the most often used method (68%), followed by biologically based topical agents (28%), and mind-body interventions (23%). Of CAM users, 54% used chondroitin, 59% used glucosamine, 12% used MSM, and 13% used vitamins/minerals nearly every day. Almost 8% reported use of energy therapies. Use of mind-body interventions was common (23%), with 12% of CAM users reporting use of methods like yoga or Tai Chi, w8% reporting techniques such as meditation or visualization, and 8% reporting spiritual activities. The distributions were similar regardless of conventional medication use except for spiritual activities which were more common among users of CAM and conventional medications (26%) than CAM only users (19%). Table II shows the characteristics of the participants by treatment approaches: conventional only, CAM only, both, or neither. The age distribution was similar across categories of CAM and conventional medication use, while differences in the gender distribution were present. Women were more likely to use any treatment (60% conventional medication only users, 61% CAM (only users, 67% both and 51% neither). The distribution of race/ethnicity was similar among those reporting use of both conventional and CAM approaches to those reporting use of neither approach. Those reporting use of conventional medications only were more likely to be Black/African American (29%), whereas users reporting only CAM use were less likely to report being Black/African American (14%) relative to non-users of either group (18%).
Relative to non-users of CAM and conventional medications, those reporting only the use of conventional medications had less education, and were less likely to report being employed. Most reported health insurance coverage, with no differences in the percent with health insurance providing prescription medication coverage by treatment approach. The distribution of BMI differed between the conventional medication only group and those reporting use of CAM and conventional medications compared to non-users of either approach. Physical summary scores were less in each treatment group relative to the group using neither approach. Table III shows the clinical and functional characteristics of the participants stratified by treatment group. Compared to participants not using any CAM therapies or conventional medications, each of the other treatment groups had higher pain scores and lower quality of life indices. While CAM only users had functional and performance indicators similar to the no treatment group, users of conventional medications and users of CAM and conventional medications took longer on the functional tests. Correspondingly, all treatment groups had worsening X-ray evidence of joint space narrowing relative to participants who reported no CAM or conventional medication use. Users of both CAM and conventional medications (29%), CAM only users (23%), conventional medication users (22%) were more likely to have severe joint space narrowing relative to non-users of CAM and conventional medicines (14%). Although overall total hip replacement was infrequent (<3%), its occurrence was greater in the conventional medication users only and in the CAM and conventional medication use group relative to the non-users. Hand OA was twice as prevalent in each of the exposure groups relative to the non-users. Hip symptoms in the past 12 months were most often reported in users of CAM and conventional medications (w36%) followed by conventional medication users only (28%), CAM only users (25%), and non-users (15%). While history of knee injury was only more common in CAM only users relative to non-users (51% vs 45%), history of knee surgery was more prevalent among conventional medication users (32%) and CAM and conventional medication users (33%) relative to non-users (26%). Table IV shows the correlates of treatment approaches among participants with radiographic-confirmed knee OA. Women were more likely than men to use any method (CAM or conventional medications). Black participants were less likely than non-Hispanic Whites to use CAM therapies either alone (aOR: 0.71; 95% CI: 0.51e1.00) or in combination (aOR: 0.54; 95% CI: 0.38e0.76). Relative to participants with a high school education or less, those who graduated from college were more likely to use strategies that included CAM (aOR CAM only: 1.64; aOR Both: 1.48). Those with higher scores on the SF-12 (physical summary) and the KOOS-QOL were less likely to receive any treatments. Total hip replacement more than tripled the likelihood of use of conventional medications, either with or without CAM. X-ray evidence of severe narrowing (OARSI grade 3) was associated with strategies using CAM (aOR CAM only: 1.63; 95% CI: 1.16e2.29; aOR Both: 1.98; 95% CI: 1.39e2.82).
The analyses in Table V further refine the classification of CAM into: (1) glucosamine or chondroitin users (with most participants reporting use of both therapies); and (2) other CAM therapies. When classified this way, women are twice as likely to report use of other CAM therapies relative to men (aOR: 2.25; 95% CI: 1.61e3.14). While Black participants were no more or less likely to report use of other CAM treatments, they were much less likely to report use of glucosamine or chondroitin (aOR: 0.39; 95% CI: 0.24e0.65). Further, those with at least a college education were twice as likely to report glucosamine/chondroitin use relative to those with a high school education or less, but education did not correlate with use of other CAM therapies. Severity of disease also did not correlate with other CAM use, but was associated with a greater likelihood of glucosamine/chondroitin use.
Discussion
We found use of CAM approaches to be common. Forty-seven percent of participants of the OAI with radiographic-confirmed OAK reported use of at least one CAM approach, which is lower than previous reports 9, 24, 25 , but similar as other studies with specific focus on OAK 26 . Estimates of CAM use from other studies vary widely (34e90% 25 ) owing to differences in the operational expression of CAM use (e.g., including prayer), differences in the time referent (e.g., ever use, use in past month), population included (e.g., all conditions vs OAK), as well as geographic differences. This study documents that persons with OAK commonly use multiple treatment approaches. Indeed, 24% reported use of at least one CAM approach in addition to conventional pharmacologic medicines and 32% of CAM users reported recent use of multiple CAM approaches. The most common CAM approach was use of biologically based supplements. Despite widespread use, patients may not disclose their use of CAM to physicians 27 and even if discussed, CAM use is not frequently documented in the medical record 28 . The extent to which herbal remedies and supplements may interact with conventional medications is non-trivial 29 . Unless CAM use is integrated into electronic medical records, averting such interactions is unlikely. Given the extent of dual use of approaches, physicians should be encouraged to ask patients about CAM use and document use. Electronic medical record systems allowing electronic prescribing should have the ability to check for such drugherb or drug-supplement interactions at the point of prescribing, as this may be the only place in the pharmacy-care process where such interactions can be detected.
We found that participants with greater physical wellbeing as measured with standardized tools including the KOOS-QOL and SF-12 had reduced use of any treatment. Indication of clinical depression was not associated with OA treatment. Although there are many accepted CAM approaches to treatment of depression 30 , increased use of CAM among persons with depression was not observed in previous research 11 or in the current study. Indeed, persons with depression were half as likely to report glucosamine/ chondroitin use. Our findings contradict previous research linking depression among persons with OA to greater health care utilization (e.g., greater contacts with primary care providers, orthopedic doctors, and CAM practitioners) 31 . These important differences between CAM and non-CAM users in co-morbid conditions, physical functioning and severity of illness will likely lead to confounding by indication when evaluating the benefits of CAM use using non-experimental paradigms. As such, novel analytic approaches to address such confounding in comparative effectiveness research of CAM must be employed.
Our study confirmed several important associations between treatment approaches and sociodemographic factors. We confirmed previous reports between gender and treatment options 32 , with greater associations noted with CAM use (either alone or in conjunction with conventional medications). As others have shown 11 , persons with more education were more likely to select treatment options including CAM. In our study, more education was associated with increased reported use of glucosamine/chondroitin. Relative to non-Hispanic Whites, Blacks were less likely to use CAM treatments (either alone or in conjunction with conventional medications) relative to no treatments. The lack of CAM use by Blacks was owing to decreased use of glucosamine/chondroitin. This finding contradicts previous reports showing that Black persons with OA are more likely to use CAM and conventional medications 9 . The extent to which our findings are subject to information bias, as others suggest 27 remains unknown. Persons with greater levels of obesity were more likely to report use of conventional medications than those with BMI < 25 k/ m 2 . Previous research 14 noted that adults with higher BMIs were no more likely to use each of the individual CAM therapy and less likely to use supplements relative to normal weight adults. This is consistent with the finding in our study that morbidly obese persons were almost half as likely to report use of glucosamine/chondroitin. Our findings must be considered with limitations in mind. The data on treatments were obtained at the same time the measures of function and pain were collected. No questions were asked about omega-3 or seal oil. This cross-sectional study precludes statements of predictors of use and associations are confounded by potential treatment effects. Recall bias of treatments among persons with OAK has been documented 33 . Treatments were based on a 30 day and 6 month recall so it is possible that participants did not accurately report the use of treatments. These concerns may have introduced misclassification in assignment of participants to the treatment approaches which would have diluted any observed associations. The OAI data do not provide information regarding whether or not CAM treatments and conventional medications were actually covered by the participants' health insurance. We were unable to evaluate the impact of insurance coverage on use of these treatments. As with other studies 34 , our findings are not generalizable to all persons with OAK owing to selective participation in research. In particular, most of the people in our sample were employed, had health insurance, and were well educated. The sample also excluded persons with severe OAK. Our study demonstrates that CAM use (with or without conventional medication use) is common in persons with radiographicconfirmed OAK, and that frequently multiple CAM approaches are used either alone or in conjunction with conventional medication use. Our finding that use of treatments is associated with severity of disease and pain indicators suggests that management of OAK may not be optimal. Sociodemographic, as well as functional and clinical factors related to pain and quality of life are correlated to choice of treatment options. Physicians caring for persons with OAK should understand their patients' CAM practices, educate patients of the latest understanding of the usefulness of CAM approaches, and discuss the potential risks associated with CAM and conventional treatments. While previous research has documented the potential adverse effects of both conventional and CAM approaches, more evidence is needed to demonstrate the effectiveness of these treatment approaches either alone or in combination with other CAM approaches 35 or conventional medications 36, 37 as the costs of treatment equal to costs of traditional medicine 26 . Our data demonstrate the need for improved overall management, and potentially greater access to total knee replacements if non-surgical approaches do not sufficiently address the patients' needs.
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